HER2 levels may aid in treatment selection for metastatic breast cancer
Tuesday, December 2, 2008 - 12:49
in Health & Medicine
Findings published in the December 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. In addition, a misclassification of metastatic breast cancer patients by as much as 10 percent prevents some people from receiving optimal therapy.
Read the whole article on Physorg
More from Physorg
Related
- HER2 levels may aid in treatment selection for metastatic breast cancerTue, 2 Dec 2008, 10:49:47 EST
- Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancerThu, 28 May 2009, 17:23:59 EDT
- Triple drug combination is promising option to treat metastatic HER2+ breast cancerFri, 15 May 2009, 9:36:18 EDT
- Vaccine against HER2-positive breast cancer offers complete protection in labMon, 15 Sep 2008, 5:36:14 EDT
- Breast density associated with increased risk of cancer recurrenceMon, 9 Nov 2009, 5:15:06 EST